Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reparixin in COVID-19 Pneumonia
NCT04794803Phase 3Terminated
- Sponsor
- Dompé
- Start
- May 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial in COVID-19 pneumonia comparing Reparixin with Standard of Care (2 arms). Primary endpoint: Percentage of Participants With Composite Endpoint of Clinical Events. Started May 2020; status: terminated.
02
Drugs
reparixin
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04794803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04794803.